Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gen3014
- Development stage
- Phase 2
- Lead developer
- Genmab
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GEN3014 (HexaBody-CD38) is a next-generation, hexamerization-enhanced human IgG1 monoclonal antibody targeting CD38. It incorporates the E430G mutation in its Fc domain, which promotes efficient antibody hexamer formation upon binding to cell surfaces. This structural modification enhances complement-dependent cytotoxicity (CDC), leading to potent tumor cell killing. GEN3014 also induces other Fc-mediated effector functions such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), trogocytosis, and apoptosis after Fc-crosslinking. Additionally, it inhibits CD38 cyclase activity, potentially relieving immune suppression in the tumor microenvironment. Developed by Genmab, GEN3014 has been investigated primarily for relapsed or refractory multiple myeloma and other hematologic malignancies[1][3][8].
- Brand names
- HexaBody-CD38HexaBody-CD-38HexaBody-CD 38HexaBody®-CD38
- Other names
- HexaBody-CD38HexaBody-CD-38HexaBody-CD 38HexaBody®-CD38
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on gen3014.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gen3014.